IJBPAS, December, 2025, 14(12): 6781-6790

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

REGULATORY REQUIREMENTS FOR NEW, EASY TO READ MEDICATION, GUIDE FOR PATIENTS-USA

HARSHITHA M*, SAHANA S T, VEDAMURTHY JOSHI and ABHISHEK B V

1: M Pharmacy, Department of Pharmaceutics & Regulatory Affairs, SACCP, ACU, B. G. Nagara, Karnataka, India

2: M Pharmacy, Department of Pharmaceutics & Regulatory Affairs, SACCP, ACU, B.G. Nagara, Karnataka, India

3: Professor, Department of Pharmaceutics & Regulatory Affairs, SACCP, ACU, B. G. Nagara, Karnataka, India

4: Assistant Professor, Department of Pharmaceutics & Regulatory Affairs, SACCP, ACU, B. G. Nagara, Karnataka, India

***Corresponding Author: Ms. Harshitha M: E Mail: harshithamuguchi@gmail.com**

Received 24th Aug. 2024; Revised 15th Oct. 2024; Accepted 19th Dec. 2024; Available online 1st Dec. 2025

https://doi.org/10.31032/IJBPAS/2025/14.12.9691

ABSTRACT

The FDA is proposing a new regulation, Patient Medication Information (PMI), to simplify medication and device information, enhancing patient understanding and adherence, promoting safety and safety in the medication guide industry. The PMI offers numerous benefits, including enhanced by treating various aspects of medication administration and patient knowledge, healthcare outcomes are improved and safety for patients is maintained. The FDA has proposed a rule to enhance patient clarity by requiring concise and easy-to-read information about a drug. The FDA discovered that existing Consumer Medication Information is not always clear to patients, despite the fact that patients often receive informational documents with their prescription medication. CDER developed a finalized PMI format for prescription drugs, focusing on key elements for patient safety and effectiveness, including medication component name, safety data, typical adverse effects, and directions for use. The FDA is investigating the use of "Patient Medication Information" (PMI), a new technique to ensure the

safe use of medical products, despite the complexity of labelling and warnings. This innovative approach seeks to improve health by giving patients easily understood, reliable, obtainable information and patient well-being and also FDA brought some of the limitations in the form of templates for better understanding the prescription and overall patient medication information template/ form as an example in the form of single sheet/one page document. Through this rule patients/consumers will take the medication without any confusion and also used in betterment of health.

Keywords: FDA, CDER, Patient Medication, Prescription, Healthcare

INTRODUCTION:

When it comes to taking pharmaceuticals, it's critical to understand what we're taking and the hazards that may arise. To that end, "the US Food and Drug Administration" (FDA) recently proposed a new rule that intends that to make pharmaceutical data easier for consumers to read and understand. The proposed regulation would force drug producers to write medication guidelines and patient information booklets in plain language so that people may make informed health decisions.

"The US Food and Drug Administration" (FDA) is proposing the new regulation that to simplify the language used in medicine and device information, allowing people to better comprehend what they are taking. This modification will greatly improve patient safety and understanding **[1]**.

The US Federal (FDA) recommends "Patient Medication Information" (PMI) as a unique kind of medication guide that will offer giving them concise, transparent information about the prescription medications they consume in order to increase patient knowledge and adherence **[2]**.

The FDA is offering to change its prescription of drug for human labelling regulations to require a unique type of medication guide—"Patient Medication Information" (PMI)- for pharmaceutical items that are used, filled, or given as outpatients; this includes blood and its components that are transfused in an outpatient environment.

PMI includes:

- To enhance public health by giving patients with appropriate, simple, easily available, and valuable patients information.
- To ensure that patients receive important data on how to utilize their prescription medications in a way that is patient-friendly, safe, and efficient.
- To produce a one-page document with consistent content and formatting so that patients can easily

access important prescription product information.

- Apart from the actual paper format, patients should have the option of receiving medication data electronically.

Information for patients:

- The FDA will approve the PMI.
- The PMI will convey patient's important information regarding the prescription medication product, including basic usage instructions.
- Patients receiving prescribed medicines would receive the FDA permitted PMI from authorized dispensers, such as pharmacists items utilized, distributed, or administered on an outpatient basis.
- PMI is available to patients in both paper and electronic formats. If a patient desires electronic delivery, the default distribution method-paper-must be provided.

Information for applicant:

- If finalized, the anticipated regulation will involve applicants of innovative and accepted NDA and BLA to produce PMI for prescriptioned medication drugs used in outpatient settings.
- With the exception of labeling variations allowed by law, the proposed regulation will require applicants of newly developed and approved abbreviated new drug applications (ANDA) to have the same PMI when referencing a reference listed medicine with FDA-approved PMI. An FDA template method will be available for ANDAs without a reference mentioned drug.
- Current Medication Guide requirements will remain in effect for proposed V-year execution of final rule schedules. However, once a treatment medication product has FDA approved patient medication information, the current regulations will no longer apply.
- PMI will substitute present medication guides and patient package inserts. It is not meant to take the place of prescribing information, instructions for use, / patient counselling.

Information for healthcare-providers:

- Patients receiving prescription medicine items as outpatients will receive FDA-approved PMI from authorized dispensers, such as pharmacists.
- Patients will have the option of receiving PMI in paper or electronic format. If a patient asks for electronic distribution.

- PMI will be electronically stored in the labeling repository maintained by the FDA at https://labels.fda.gov. Paper is the standard distribution medium.
- PMI is not required for patients using prescription medications in an inpatient setting, such as a nursing facility or hospital. For prescription drug goods, such as those used by outpatients, that a patient keeps at home, PMI distribution is necessary.
- Patient package inserts and medication guides will be replaced by PMI. The Prescription Data the Directions for Use, and patient counseling are not meant to be replaced by PMI **[3]**.

One-page documentation would provide patients with necessary information in a standardized manner, such as:

- Biological/Drug product name
- Summary of the uses and indications in brief
- Important information on safety
- Common side effects/ side effects
- Directions for use/ instructions for use **[4]**.

Significant features of the Easy-to-Read Medication Guide

The PMI's significant features include:

• **Simple and Clear Terminology:** Instead of using complex medical terms, the new handbook will express pharmaceutical information in plain language. Patients will be more likely to understand the goal, dosage, side effects, and possible risks of the medications they are prescribed if medical terms are eliminated and instructions are made simpler.

• **Visual Aids:** The PMI will emphasize important subjects with the use of visual aids including diagrams, images, and icons. For those who have vision problems or find it difficult to understand written material, visual tools can be quite helpful.

• **Logical Structure:** The data in the manual will be presented in a clear and logical order. Patients will find it easier to navigate the page and find the exact information they need, like precautions, storage guidelines, and dosing instructions.

• **Translation and Accessible:** To better serve a variety of patient populations, the PMI will be translated into other languages. The FDA also plans to make the manual accessible to people with disabilities, especially those who may use assistive equipment such as monitor readers or braille languages due to visual impairments.

PMI benefits:

The PMI holistic method has the probable to significantly improve safety of patient and health-care outcomes by talking multiple elements of medicine administration and also patient comprehension.

The PMI's can assist;

- Decrease nonadherence to medicine,
- Patient comprehension of medicine should be improved,
- Improve interaction with medical professionals
- Errors should be prevented in medication and
- Enhance the health of the patient **[5]**.

Objectives:

- To identify the limitations of current informational documents (such as consumer medication information, medication guides, and patient package inserts) in providing easily understood information to patients
- To comprehend the PMI framework and development process by center for drug evaluation and research (CDER) for PMI.

RESULTS AND DISCUSSION:

There are numerous forms of data that a patient might obtain when prescription is complete. These are patient package inserts (PPI), medication guides (MG), and consumer medication information (CMI). Some patients may take their prescribed prescriptions incorrectly as a result of the details provided in these documents being confusing, repetitious, lacking, or contradicting. A patient's comprehension of the prescription medicine is essential to their potential to use the medication as intended, even though studies have found a number of reasons why some patients might not take their prescriptions as directed. Lack of clarity in communication regarding prescription drug may cause patients to not take them as prescribed, which could increase stays in hospitals, treatment failures, and potentially the number of deaths in the US.

The FDA announced a proposed rule on PMI to improve clarity for patients. The goal of PMI is to give patients the information they need about the drug in a clear and easy-to-read style **[6]**.

Currently, customers obtain the following documentation at the moment of administration:

- **Patient package inserts (PPI):** Prescription data created by producers, revised and permitted by the food and drug administration (FDA), and necessary for certain medications or groups of drugs (oral contraceptive and estrogen containing product). Some other PPIs are created and drug is submitted by manufacturers voluntarily, and the FDA reviews and approves them.
- **Consumer medication information (CMI):** Prescription info written by pharmacists or a III party that have not been FDA

reviewed or accepted and is willingly supplied to customers.

- **Medication guides:** Prescription info provided by manufacturer for medication "that pose a serious and significant public health concern." The FDA reviews and approves medication guidelines, which should be supplied to consumer every time a medicine is distributed **[7]**.
- **Instructions for use:** Applicant may create an instruction for use documents for prescription drugs with complex or thorough patient instructions. The FDA reviews and approves the Instructions for Use document, which is normally presented to the patient when the medicine is dispensed **[8]**.

Sample template for patient labelling includes;

1. Medication guides
2. Patient package inserts
3. Instructions for use **[9]**.



MEDICATION GUIDE

DRUG-X (pronunciation spelling)

Injection, for intramuscular use

What is the most important information I should know about DRUG-X? .....

What is DRUG-X? .....

Who should not take DRUG-X? .....

Before taking DRUG-X, tell your healthcare provider about all of your medical conditions, including if you: .....

How should I take DRUG-X? .....

What should I avoid while taking DRUG-X? .....

What are the possible side effects of DRUG-X? .....

Call doctor for medical advice about side effects. Can report side effects to FDA

How should I store DRUG-X? .....

General information about the safe and effective use of DRUG-X.

Medicines are sometimes prescribed for purposes other than those listed in a medication guide. Do not use DRUG-X for a condition for which it was not prescribed. Do not give DRUG-X to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about DRUG-X that is written for health professionals.

What are the ingredients in DRUG-X?

Active ingredients:

Inactive ingredients:

Manufactured for and by:

PATIENT INFORMATION

DRUG-X (pronunciation spelling)

(a and b tablets)

For oral use

What is DRUG-X? .....

Do not take DRUG-X if you: .....

Before taking DRUG-X, tell your healthcare provider about all of your medical conditions, including if you: .....

How should I take DRUG-X? .....

What should I avoid while taking DRUG-X? ....

What are the possible side effects of DRUG-X? .... Call your doctor for medical advice about side effects. You may report side effects to FDA

How should I store DRUG-X? ....

General information about the safe and effective use of DRUG-X.

Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use DRUG-X for a condition for which it was not prescribed. Do not give DRUG-X to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about DRUG-X that is written for health professionals.

What are the ingredients in DRUG-X?

Active ingredients:

Inactive ingredients:

Manufactured for and by:

INSTRUCTIONS FOR USE

MYDRUG [mye-drug]

(drugoxide infection)

For intramuscular use

This instructions for use contain information on how to take MYDRUG.

Important information you need to know before taking MYDRUG.....

Preparing to take MYDRUG.....

Taking MYDRUG.....

Storing MYDRUG.....

Disposing of MYDRUG.....

Drug company X, city, state, zip code

This instructions for use have been approved by the U. S. Food and Drug Administration.

Approved: MM/YYYY

Figure 1: Examples of sample templates of medication guide, patient information, instructions for use

PMI Framework

1. Development
2. Central Repository
3. Distribution
4. Quality Surveillance

1. Development

- The product producer develops content, format, and testing standards.
- Example format: one-page, black ink, and minimum letter size (10).
- Example content: approved prescribing information with predefined headings.

2. **Central Repository**
   - A reliable PMI data source
   - Open access for consumers, healthcare providers, and pharmacists
   - Data standards that control format and content.
   - The National Library of Medicine is an important stakeholder in development.
3. **Distribution**

   Distribution possibilities include:
   - Pharmacy in paper and electronic formats
   - Online via email or QR code
   - Patient electronic health records.
4. **Quality Surveillance**

   Potential approaches include
   - FDA approval,
   - Material based on approved prescribing information, and
   - Consumer comprehension testing **[10]**.

Some of the examples by the patients who felt difficulty to understand the information in medication guides:

1. When John received a medicine guide for chronic pain, he felt overwhelmed by the amount of information. He couldn't understand what he needed to do and end up neglecting doses.

2. Jane was prescribed medication to treat her depression. She failed to comprehend the instructions on her medicine guide and took too much, making her feel worse.

3. Bill was concerned about the negative effects of his new prescription and attempted to study the guide, but the complex language caused confusion and frustration **[1]**.

PMI Examples for hypothetical drug products: The following hypothetical product example was created during the proposed regulation's development and might not accurately represent the specifications of the final rule, should it be issued **[3]**.

PATIENT MEDICATION INFORMATION RHEUTOPIA (arixalate injection, for subcutaneous use)
RHEUTOPIA Is: Information about the rheutopia ……..
Important Safety Information **Warnings: …….** **Serious side effects: …….** **If you have any adverse reaction inform your healthcare provider before taking: ……..**
Common Side Effects …….
Directions for Use …….
Manufactured by: Drug Company Name, City, State Zip Code

Figure 2: Patient medication information template with rheutopia as example

Patients are frequently given instructional leaflets alongside their prescription medication to aid them to take their medicines carefully and efficiently. These products are aimed to prevent potentially harmful pharmaceutical reactions and enhance health outcomes. However, the FDA observed that current Consumer Medication Information is not always clear to patients.

"The information in these documents can be difficult to understand, repetitive, incomplete, or conflicting, which may cause some patients to take their prescription medication incorrectly," said Christopher Diamant, JD, regulatory guidance for the center for drug evaluation and research (CDER) Office of Medical Plan. "Although studies have revealed a diversity of reasons why some consumers do not take their prescriptions as recommended, an individual's comprehension of a prescription medication has a significant impact on patients' ability to use the drugs as intended. Communication is unclear regarding pharmaceutical prescriptions could end up in patient failure to adhere may be the cause of increased annual hospitalizations, treatment failures, and even rates of mortality in the US.

To develop a PMI, CDER conducted research and collected feedback from a variety of stakeholders to build document prototypes. Diamant noted that patients prefer a concise, one-page style since longer information packets are more difficult to process.

After conducting research and workshops, CDER concentrated on essential components for patient safety and efficacy when using prescription drugs. The finalized PMI format comprises sections for the medicine's name, importance of safety information, Common adverse effect, and instructions for usage.

"Patients might receive PMI if they obtained prescription medications in an outpatient environment, including pharmacies that offer retail or hospital outpatient care. The FDA-approved PMI would be given out by authorized dispensers, including pharmacists, along with prescription drugs. Transfusion clinics are required by Diamant to provide PMI to all outpatient patients obtaining blood or components of blood.

Patients have the choice of receiving PMI in paper or electronic format; paper is sent by default unless an electronic delivery method is specified. Medication guides and patient package inserts will eventually be replaced by PMI; however, patient counseling, instructions for use, and prescribing information will not be replaced. The PMI will be kept in a CDER-managed online central repository and made available to the public, with the opportunity to download in batches for convenience **[2]**.

CONCLUSION:

In conclusion, the legal requirements for a modern, user-friendly medication guide for patients involve careful attention to clarity, accuracy, and accessibility. By complying to these guidelines, pharmaceutical companies can provide patients with critical information in a way that encourages comprehension and informed healthcare decisions. Adopting these standards not only improves patient safety, but also encourages trust and transparency in the healthcare system, resulting in better health outcomes and patient well-being.

To ensure the safe use of medical products, the FDA implements restrictions such as labelling and warnings. Labeling, however, is frequently complex and difficult for laypeople to comprehend. "Patient Medication Information" (PMI) is a novel technique that the FDA has been investigating since 2017. This investigation has been going on for a while even after developing the proposed rule.

ACKNOWLEDGEMENT:

The author wants to acknowledge the management of Sri Adichunchanagiri College of Pharmacy for their valuable support.

CONFLICTS OF INTEREST:

The authors declared that there is no conflict of interest.

REFERENCES:

[1] FDA Announces New Reg. for Easy-to-Understand Medication Info for Patients [Internet]. [cited 2024 Jun 11]. Available from: https://msbdocs.com/security-compliance/fda-proposes-easier-patient-medication-guide/

[2] Hmpgloballearningnetwork.com. 2024 [cited 2024 Jun 11]. Available from: https://www.hmpgloballearningnetwork.com/site/pln/news/fda-proposes-new-patient-medication-

information-guide-improve-patient-understanding

[3] Research C for DE and. Patient Medication Information (PMI). FDA [Internet]. 2024; Available from: https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/patient-medication-information-pmi

[4] FDA Proposes New, Easy-to-Read Medication Guide for Patients, patient Medication Information. American Pharmaceutical Review 2023.Available from: https://www.americanpharmaceuticalreview.com/1315-News/597345-FDA-Proposes-New-Easy-to-Read-Medication-Guide-for-Patients-Patient-Medication-Information/

[5] FDA Proposes New, Easy-to-Read Medication Guide for Patients [Internet]. www.propharmagroup.com. [cited 2024 Jun 11]. Available from: https://www.propharmagroup.com/thought-leadership/fda-proposes-new-easy-to-read-medication-guide-for-patients

[6] Research C for DEA. Patient Medication Information: A 2023 Proposed Rule to Help Patients Understand Their Prescription Medication Information. US Food and Drug Administration 2024. https://www.fda.gov/drugs/cder-conversations/patient-medication-information-2023-proposed-rule-help-patients-understand-their-prescription.

[7] Exploring the Promise of Patient Medication Information. (2014). https://www.brookings.edu/wp-content/uploads/2014/05/PMI-Meeting-71-Agenda-and-Discussion-Guide.pdf

[8] Federal Register: Request Access. (n.d.). Unblock.federalregister.gov. https://www.federalregister.gov/documents/2023/05/31/2023-11354/medication-guides-patient-medication-information

[9] Research, C. for D. E. and. (2022). Patient Labelling Resources. *FDA*. https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/patient-labeling-resources

[10] Exploring the Promise of Patient Medication Information. (2014). https://www.brookings.edu/wp-content/uploads/2014/05/PMI-Final-Presentation-20140702-updated-2.pdf